Advancing drug discovery for schizophrenia

Stephen R. Marder; Bryan Roth; Patrick F. Sullivan; Edward M. Scolnick; Eric J. Nestler; Mark A. Geyer; Daniel R. Welnberger; Maria Karayiorgou; Alessandro Guidotti; Jay Gingrich; Schahram Akbarian; Robert W. Buchanan; Jeffrey A. Lieberman; P. Jeffrey Conn; Stephen J. Haggarty; Amanda J. Law; Brian Campbell; John H. Krystal; Bita Moghaddam; Akira Saw; Marc G. Caron; Susan R. George; John A. Allen; Michelle Solis

doi:10.1111/j.1749-6632.2011.06216.x

Advancing drug discovery for schizophrenia

Stephen R. Marder, Bryan Roth, Patrick F. Sullivan, Edward M. Scolnick, Eric J. Nestler, Mark A. Geyer, Daniel R. Welnberger, Maria Karayiorgou, Alessandro Guidotti, Jay Gingrich, Schahram Akbarian, Robert W. Buchanan, Jeffrey A. Lieberman, P. Jeffrey Conn, Stephen J. Haggarty, Amanda J. Law, Brian Campbell, John H. Krystal, Bita Moghaddam, Akira SawMarc G. Caron, Susan R. George, John A. Allen, Michelle Solis

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

Original language	English (US)
Pages (from-to)	30-43
Number of pages	14
Journal	Annals of the New York Academy of Sciences
Volume	1236
Issue number	1
DOIs	https://doi.org/10.1111/j.1749-6632.2011.06216.x
State	Published - Oct 2011
Externally published	Yes

Keywords

GWAS
Genetics
Neuronal function
Schizophrenia
Small molecules
Therapeutics

ASJC Scopus subject areas

General Neuroscience
General Biochemistry, Genetics and Molecular Biology
History and Philosophy of Science

Access to Document

10.1111/j.1749-6632.2011.06216.x

Cite this

Marder, S. R., Roth, B., Sullivan, P. F., Scolnick, E. M., Nestler, E. J., Geyer, M. A., Welnberger, D. R., Karayiorgou, M., Guidotti, A., Gingrich, J., Akbarian, S., Buchanan, R. W., Lieberman, J. A., Conn, P. J., Haggarty, S. J., Law, A. J., Campbell, B., Krystal, J. H., Moghaddam, B., ... Solis, M. (2011). Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences, 1236(1), 30-43. https://doi.org/10.1111/j.1749-6632.2011.06216.x

Marder, SR, Roth, B, Sullivan, PF, Scolnick, EM, Nestler, EJ, Geyer, MA, Welnberger, DR, Karayiorgou, M, Guidotti, A, Gingrich, J, Akbarian, S, Buchanan, RW, Lieberman, JA, Conn, PJ, Haggarty, SJ, Law, AJ, Campbell, B, Krystal, JH, Moghaddam, B, Saw, A, Caron, MG, George, SR, Allen, JA & Solis, M 2011, 'Advancing drug discovery for schizophrenia', Annals of the New York Academy of Sciences, vol. 1236, no. 1, pp. 30-43. https://doi.org/10.1111/j.1749-6632.2011.06216.x

@article{a6f623cc0d164cc3b930110d92127f7e,

title = "Advancing drug discovery for schizophrenia",

abstract = "Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, {"}Advancing Drug Discovery for Schizophrenia{"} was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.",

keywords = "GWAS, Genetics, Neuronal function, Schizophrenia, Small molecules, Therapeutics",

author = "Marder, {Stephen R.} and Bryan Roth and Sullivan, {Patrick F.} and Scolnick, {Edward M.} and Nestler, {Eric J.} and Geyer, {Mark A.} and Welnberger, {Daniel R.} and Maria Karayiorgou and Alessandro Guidotti and Jay Gingrich and Schahram Akbarian and Buchanan, {Robert W.} and Lieberman, {Jeffrey A.} and Conn, {P. Jeffrey} and Haggarty, {Stephen J.} and Law, {Amanda J.} and Brian Campbell and Krystal, {John H.} and Bita Moghaddam and Akira Saw and Caron, {Marc G.} and George, {Susan R.} and Allen, {John A.} and Michelle Solis",

year = "2011",

month = oct,

doi = "10.1111/j.1749-6632.2011.06216.x",

language = "English (US)",

volume = "1236",

pages = "30--43",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Advancing drug discovery for schizophrenia

AU - Marder, Stephen R.

AU - Roth, Bryan

AU - Sullivan, Patrick F.

AU - Scolnick, Edward M.

AU - Nestler, Eric J.

AU - Geyer, Mark A.

AU - Welnberger, Daniel R.

AU - Karayiorgou, Maria

AU - Guidotti, Alessandro

AU - Gingrich, Jay

AU - Akbarian, Schahram

AU - Buchanan, Robert W.

AU - Lieberman, Jeffrey A.

AU - Conn, P. Jeffrey

AU - Haggarty, Stephen J.

AU - Law, Amanda J.

AU - Campbell, Brian

AU - Krystal, John H.

AU - Moghaddam, Bita

AU - Saw, Akira

AU - Caron, Marc G.

AU - George, Susan R.

AU - Allen, John A.

AU - Solis, Michelle

PY - 2011/10

Y1 - 2011/10

N2 - Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

AB - Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

KW - GWAS

KW - Genetics

KW - Neuronal function

KW - Schizophrenia

KW - Small molecules

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=80055004719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055004719&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2011.06216.x

DO - 10.1111/j.1749-6632.2011.06216.x

M3 - Article

C2 - 22032400

AN - SCOPUS:80055004719

SN - 0077-8923

VL - 1236

SP - 30

EP - 43

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

IS - 1

ER -

Advancing drug discovery for schizophrenia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this